Comparative Effectiveness of Generic vs Brand-Name Levothyroxine in Achieving Normal Thyrotropin Levels

被引:17
作者
Brito, Juan P. [1 ]
Ross, Joseph S. [2 ,3 ,4 ,5 ]
Sangaralingham, Lindsey [6 ]
Dutcher, Sarah K. [7 ]
Graham, David J. [7 ]
Wang, Zhong [8 ]
Wu, Yute [9 ]
Yao, Xiaoxi [6 ,10 ]
Smallridge, Robert C. [11 ]
Bernet, Victor [11 ]
Shah, Nilay D. [6 ,10 ,12 ]
Lipska, Kasia J. [5 ,13 ]
机构
[1] Mayo Clin, Dept Internal Med, Div Endocrinol Diabet Metab & Nutr, Knowledge & Evaluat Res Unit, 200 First St SW, Rochester, MN 55905 USA
[2] Yale Sch Med, Sect Gen Internal Med, New Haven, CT USA
[3] Yale Sch Med, Natl Clinician Scholars Program, New Haven, CT USA
[4] Yale Sch Publ Hlth, Dept Hlth Policy & Management, New Haven, CT USA
[5] Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT USA
[6] Mayo Clin, Robert D & Patricia E Kern Ctr Sci Hlth Care Deli, Rochester, MN USA
[7] US FDA, Off Surveillance & Epidemiol, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[8] US FDA, Off Res & Stand, Off Gener Drugs, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[9] US FDA, Off Biostat, Off Translat Sci, Ctr Drug Evaluat & Res, Silver Spring, MD USA
[10] Mayo Clin, Div Hlth Care Policy & Res, Rochester, MN USA
[11] Mayo Clin, Div Endocrinol, Jacksonville, FL USA
[12] Optum Labs, Cambridge, MA USA
[13] Yale Sch Med, Dept Internal Med, Sect Endocrinol, New Haven, CT USA
关键词
UNITED-STATES; TASK-FORCE;
D O I
10.1001/jamanetworkopen.2020.17645
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
This cohort study compares the effectiveness of generic vs brand-name levothyroxine in achieving and maintaining normal thyrotropin levels among new users. Importance Whether the use of generic vs brand levothyroxine affects thyrotropin levels remains unclear. Objective To compare the effectiveness of generic vs brand levothyroxine in achieving and maintaining normal thyrotropin levels among new users. Design, Setting, and Participants This retrospective, 1:1 propensity score-matched longitudinal cohort study used the OptumLabs Data Warehouse administrative claims database linked to laboratory results from commercially insured and Medicare Advantage enrollees throughout the United States. Eligible patients were adults (aged >= 18 years) with thyrotropin levels ranging from 4.5 to 19.9 mIU/L who initiated use of generic or brand-name levothyroxine from January 1, 2008, to October 1, 2017. Data were analyzed from August 13, 2018, to October 25, 2019. Exposure Patients received generic or brand-name levothyroxine. Main Outcomes and Measures Proportion of patients with normal vs markedly abnormal thyrotropin levels (10 mIU/L) within 3 months and with stable thyrotropin levels within 3 months after the thyrotropin value fell into the normal range. Results A total of 17 598 patients were included (69.0% female; 74.0% White; mean [SD] age, 55.1 [16.0] years), of whom 15299 filled generic and 2299 filled brand-name levothyroxine prescriptions during the study period. Among 4570 propensity score-matched patients (mean [SD] age, 50.3 [13.8] years; 3457 [75.6%] female; 3510 [76.8%] White), the proportion with normal thyrotropin levels within 3 months of filling levothyroxine prescriptions was similar for patients who received generic vs brand-name levothyroxine (1722 [75.4%; 95% CI, 71.9%-79.0%] vs 1757 [76.9%; 95% CI, 73.4%-80.6%]; P = .23), as was the proportion with markedly abnormal levels (94 [4.1%; 95% CI, 3.4%-5.0%] vs 88 [3.9%; 95% CI, 3.1%-4.7%]; P = .65). Among 1034 propensity score-matched patients who achieved a normal thyrotropin value within 3 months of initiation of levothyroxine, the proportion maintaining subsequent normal thyrotropin levels during the next 3 months was similar for patients receiving generic vs brand-name levothyroxine (427 [82.6%] vs 433 [83.8%]; P = .62). Conclusions and Relevance Initiation of generic vs brand-name levothyroxine formulations was associated with similar rates of normal and stable thyrotropin levels. These results suggest that generic levothyroxine as initial therapy for mild thyroid dysfunction is as effective as brand-name levothyroxine. Question What is the comparative effectiveness of generic vs brand-name levothyroxine in achieving normal thyrotropin levels? Findings In a cohort study of 17 598 patients from a national administrative claims database, a similar proportion of generic vs brand-name levothyroxine users achieved target thyrotropin levels. Meaning These findings suggest that initiation of generic or brand levothyroxine for mild thyroid dysfunction is associated with similar rates of achieving target laboratory outcomes.
引用
收藏
页数:12
相关论文
共 20 条
[1]  
Association for Accessible Medicines, 2018, GEN DRUG ACC SAV US
[2]   Good Research Practices for Comparative Effectiveness Research: Defining, Reporting and Interpreting Nonrandomized Studies of Treatment Effects Using Secondary Data Sources: The ISPOR Good Research Practices for Retrospective Database Analysis Task Force Report-Part I [J].
Berger, Marc L. ;
Mamdani, Muhammad ;
Atkins, David ;
Johnson, Michael L. .
VALUE IN HEALTH, 2009, 12 (08) :1044-1052
[3]   A 2013 Survey of Clinical Practice Patterns in the Management of Primary Hypothyroidism [J].
Burch, Henry B. ;
Burman, Kenneth D. ;
Cooper, David S. ;
Hennessey, James V. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (06) :2077-2085
[4]   The Colorado thyroid disease prevalence study [J].
Canaris, GJ ;
Manowitz, NR ;
Mayor, G ;
Ridgway, EC .
ARCHIVES OF INTERNAL MEDICINE, 2000, 160 (04) :526-534
[5]   Generic and Brand-Name L-Thyroxine Are Not Bioequivalent for Children With Severe Congenital Hypothyroidism [J].
Carswell, Jeremi M. ;
Gordon, Joshua H. ;
Popovsky, Erica ;
Hale, Andrea ;
Brown, Rosalind S. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (02) :610-617
[6]   ADAPTING A CLINICAL COMORBIDITY INDEX FOR USE WITH ICD-9-CM ADMINISTRATIVE DATABASES [J].
DEYO, RA ;
CHERKIN, DC ;
CIOL, MA .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (06) :613-619
[7]  
Endocrine Society, 2008, BIOEQ SOD LEV END SO
[8]   Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement [J].
Jonklaas, Jacqueline ;
Bianco, Antonio C. ;
Bauer, Andrew J. ;
Burman, Kenneth D. ;
Cappola, Anne R. ;
Celi, Francesco S. ;
Cooper, David S. ;
Kim, Brian W. ;
Peeters, Robin P. ;
Rosenthal, M. Sara ;
Sawka, Anna M. .
THYROID, 2014, 24 (12) :1670-1751
[9]   Trends in Prescription Drug Use Among Adults in the United States From 1999-2012 [J].
Kantor, Elizabeth D. ;
Rehm, Colin D. ;
Haas, Jennifer S. ;
Chan, Andrew T. ;
Giovannucci, Edward L. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (17) :1818-1831
[10]  
Melmed S., 2011, WILLIAMSTEXTBOOK END, V12th ed, P348